2023-04-25 | Hepatic Impairment Study Accepted for Presentation at Major Radiology and Liver Conferences PDF Report Presentation Webcast
2023-03-14 | Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Market – Next Steps Towards Launch PDF PDF Report Presentation Webcast
2023-03-13 | Third US patent strengthens patent protection for Ascelia Pharma’s Oncoral (daily tablet irinotecan) PDF Report Presentation Webcast
2023-03-06 | INVITATION TO ASCELIA PHARMA INVESTOR UPDATE: BRINGING ORVIGLANCE TO MARKET – NEXT STEPS TOWARDS LAUNCH PDF Report Presentation Webcast
2023-03-03 | Ascelia Pharma achieves Last Patient Last Visit (LPLV) in the Orviglance Phase 3 SPARKLE Study which now includes 85 completed patients. PDF Report Presentation Webcast
2023-02-24 | Ascelia Pharma meets major milestone with patient enrollment completion for Orviglance Phase 3 Study, SPARKLE PDF Report Presentation Webcast
Regulatory 2023-02-21 | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program PDF Report Presentation Webcast
Regulatory 2022-12-02 | Nomination Committee appointed for AGM 2023 in Ascelia Pharma AB PDF Report Presentation Webcast
2022-11-30 | ASCELIA PHARMA PRESENTS RESULTS OF ORVIGLANCE FOOD EFFECT STUDY AT RSNA 2022 SHOWING STRONG LIVER ENHANCEMENT BOTH WITH LIGHT MEAL AND IN FASTING CONDITION PDF Report Presentation Webcast
2022-09-28 | Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study PDF Report Presentation Webcast
2022-08-11 | Ascelia Pharma to present Orviglance Food Effect Study at 2022 RSNA Annual Meeting PDF Report Presentation Webcast
2022-06-01 | Results from Orviglance comparison study to gadolinium presented at ESGAR 2022 conference PDF PDF Report Presentation Webcast
2022-05-31 | Ascelia Pharma second US patent for Oncoral (oral irinotecan) strengthens coverage PDF Report Presentation Webcast
2022-05-10 | Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal PDF Report Presentation Webcast
2022-03-22 | New independent market research says 84% US healthcare professionals likely to use Orviglance imaging agent in target population PDF PDF Report Presentation Webcast
2022-03-11 | Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study PDF Report Presentation Webcast
